K. Weisel Et Al. , "Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison," LEUKEMIA & LYMPHOMA , no.4, pp.481-492, 2024
Weisel, K. Et Al. 2024. Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. LEUKEMIA & LYMPHOMA , no.4 , 481-492.
Weisel, K., Dimopoulos, M. A., BEKSAÇ, M., Leleu, X., Richter, J., Heeg, B., ... Patel, S.(2024). Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison. LEUKEMIA & LYMPHOMA , no.4, 481-492.
Weisel, Katja Et Al. "Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison," LEUKEMIA & LYMPHOMA , no.4, 481-492, 2024
Weisel, Katja Et Al. "Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison." LEUKEMIA & LYMPHOMA , no.4, pp.481-492, 2024
Weisel, K. Et Al. (2024) . "Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison." LEUKEMIA & LYMPHOMA , no.4, pp.481-492.
@article{article, author={Katja Weisel Et Al. }, title={Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison}, journal={LEUKEMIA & LYMPHOMA}, year=2024, pages={481-492} }